Drug-sensitive<i>FGFR2</i>mutations in endometrial carcinoma

Amit Dutt, Helga B. Salvesen, Tzu-Hsiu Chen, +22

Proceedings of the National Academy of Sciences

AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination

Michael C. Haffner, David Esopi, Alcides Chaux, +20

Nature Communications

CytoskeletonCancer BiologyAim1 DeletionCellular PhysiologyTumor Biology +17

Generation and multiomic profiling of a<i>TP53/CDKN2A</i>double-knockout gastroesophageal junction organoid model

Hua Zhao, Yulan Cheng, Andrew Kalra, +16

Science Translational Medicine

TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers

Tushar D. Nichakawade, Jiaxin Ge, Brian J. Mog, +23

Nature

Tumor ImmunologyCancer ImmunosurveillanceDrug TargetingMedicineImmunology +8

Time-Resolved Fluorescence Resonance Energy Transfer Assay for Discovery of Small-Molecule Inhibitors of Methyl-CpG Binding Domain Protein 2

Nicolas Wyhs, David R. Walker, Hugh Giovinazzo, +2

SLAS DISCOVERY

Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities

Brian J. Mog, Nikita Marcou, Sarah R. DiNapoli, +21

Science Translational Medicine

A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs

Hugh Giovinazzo, David R. Walker, Nicolas Wyhs, +8

Oncotarget

Drug TargetEpigenetic ChangeDna MethylationMolecular BiologyCancer Biology +21

Biobanking of derivatives from radical retropubic and robot‐assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network

Medha S. Darshan, Qizhi Zheng, Helen Fedor, +8

The Prostate

Phenotypic characterization of two novel cell line models of castration‐resistant prostate cancer

Michael C. Haffner, Akshay Bhamidipati, Harrison Tsai, +14

The Prostate

An isogenic cell line panel for sequence-based screening of targeted anticancer drugs

Ashley L. Cook, Nicolas Wyhs, Surojit Sur, +9

iScience